Printer Friendly
The Free Library
14,505,384 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

New Study Results Reaffirms Diachrome(R) Significantly Improves Cardiovascular Disease Risk Factors in People with Type 2 Diabetes.


NEW YORK -- Results of Clinical Trial Examining Effects of Diachrome on Atherogenic ath·er·o·gen·ic
adj.
Initiating, increasing, or accelerating atherogenesis.


atherogenic adjective Referring to the ability to initiate or accelerate atherogenesis—the deposition of atheromas, lipids, and
 Index of Plasma Presented at 2nd International Symposium on Triglycerides Triglycerides
Fatty compounds synthesized from carbohydrates during the process of digestion and stored in the body's adipose (fat) tissues. High levels of triglycerides in the blood are associated with insulin resistance.
 and HDL (Hardware Description Language) A language used to describe the functions of an electronic circuit for documentation, simulation or logic synthesis (or all three). Although many proprietary HDLs have been developed, Verilog and VHDL are the major standards.  

Nutrition 21, Inc. (Nasdaq: NXXI) reported today results from a new clinical study that add to the growing body of clinical data demonstrating that daily supplementation with Diachrome(R), a combination of chromium picolinate and biotin biotin: see vitamin; coenzyme.
biotin

Organic compound, part of the vitamin B complex, essential for growth and well-being in animals and some microorganisms.
, can significantly reduce cardiovascular disease risk factors in people with type 2 diabetes type 2 diabetes
n.
See diabetes mellitus.
. Findings from the randomized ran·dom·ize  
tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es
To make random in arrangement, especially in order to control the variables in an experiment.
 double-blind, placebo-controlled trial, were presented at the 2nd International Symposium on Triglycerides and HDL: Role in Cardiovascular Disease and the Metabolic Syndrome in New York, a meeting organized by the Giovanni Lorenzini Medical Foundation that is attended by both U.S. and international cardiologists and lipid specialists.

The study results presented include an analysis of subjects with type 2 diabetes who were moderately obese and taking oral antidiabetic medications. When Diachrome was added to daily treatment regimens, the atherogenic index of plasma (AIP AIP acute intermittent porphyria.
AIP Acute intermittent porphyria
), a predictive marker for cardiovascular disease that examines triglyceride and HDL cholesterol levels (good cholesterol), was significantly lower compared with the placebo group. The AIP in the Diachrome group dropped from 1.15 to 1.06, while it increased from 1.27 to 1.55 in the placebo group. A significant difference in triglycerides and cholesterol levels was also observed between the groups.

"These results support previous findings that Diachrome can serve as a safe and effective nutritional adjunct to medication in helping to lower triglyceride and cholesterol levels in people with type 2 diabetes," said study investigator Jeffrey Geohas, Medical Director, Chicago Research Center. "The ability for Diachrome to reduce these risk factors is important in this population because heart disease is the leading cause of death in patients who suffer from diabetes," said Dr. Geohas.

Nutrition 21, Inc. conducted the study in collaboration with the Chicago Research Center. "This study underscores the promise of Diachrome in helping to prevent cardiovascular disease in people with type 2 diabetes," said Gail Montgomery, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  of Nutrition 21. "As we share the wealth of clinical data demonstrating the benefits of Diachrome for people with type 2 diabetes, we anticipate that physicians will be eager to incorporate the product into clinical practice."

Diachrome is a nutritional supplement specifically formulated for people with diabetes. It contains 600 mcg of chromium as Chromax(R) chromium picolinate and 2 mg of biotin. These two compounds are both Generally Recognized as Safe Generally Recognized as Safe (GRAS) is a United States of America Food and Drug Administration (FDA) designation that a chemical or substance added to food is considered safe by experts, and so is exempted from the usual Federal Food, Drug, and Cosmetic Act (FFDCA) food  (GRAS GRAS - A public domain graph-oriented database system for software engineering applications from RWTH Aachen. ) for use as ingredients in food and supplements. It is available for purchase by calling 1-866-DIACHROME or at www.diachrome.com.

About the Atherogenic Index of Plasma

AIP is an index used to measure the atherogenicity of plasma by examining the ratio of triglycerides to HDL cholesterol (good cholesterol). It identifies the risk for atherogenesis atherogenesis /ath·ero·gen·e·sis/ (-jen´e-sis) formation of atheromatous lesions in arterial walls.atherogen´ic

ath·er·o·gen·e·sis
n.
 (fat build up in the arteries), particularly in diabetes patients and is recognized as a predictor for heart attack. The measurement reflects the delicate balance of metabolic interactions with the whole lipoprotein complex. Physicians currently utilize AIP in clinical practice to quantify response to therapeutic interventions.

About Nutrition 21

Nutrition 21 is a nutritional bioscience company and the maker of chromium-based supplements with health benefits substantiated by clinical research. The company markets Chromax chromium picolinate, which is the most-studied form of the essential mineral chromium. Nutrition 21 also developed Diachrome, which is available through diabetes educators or at www.diachrome.com. Nutrition 21 holds 36 patents for nutrition products and uses, 27 of which are for chromium compounds and their uses. More information is available at www.nutrition21.com.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jul 18, 2005
Words:592
Previous Article:Clorox Ads Honored at Cannes Lions International Advertising Festival; Loss of TV Color and a Mischievous Boy Generate Recognition at Prestigious...
Next Article:Fred Reynolds Joining Evercore as President & Chief Operating Officer.



Related Articles
SNDA FILED FOR XENICAL AS TYPE 2 DIABETES TREATMENT OPTION.
Air pollution is a serious cardiovascular risk.(EH Update)
A systematic approach to managing hypertension and the metabolic syndrome in primary care.(Original Article)
Predictive power of cardiovascular risk factors for detecting peripheral vascular disease.(Original Article)
Type 2 diabetes: epidemiologic trends, evolving pathogenic concepts, and recent changes in therapeutic approach.(Review Article)
The role of inflammation in diabetes and its complications.(Editorial)
Improving antihypertensive therapy in patients with diabetic nephropathy.(CME Topic)
Peripheral arterial disease in patients with diabetes mellitus.(Editorial)(medical research)(Editorial)
Early use of insulin in the management of type 2 diabetes--the time is now.(Disease/Disorder overview)(Editorial)
The impact of diabetes mellitus on endothelial dysfunction.(Editorial)

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles